Siponimod for patients with relapsing-remitting multiple sclerosis (BOLD): An adaptive, dose-ranging, randomised, phase 2 study

The Lancet Neurology

Volumn 12, Issue 8, 2013, Pages 756-767

  Selmaj, Krzysztof ^a   Li, David KB ^b   Hartung, Hans Peter ^c   Hemmer, Bernhard ^d   Kappos, Ludwig ^e   Freedman, Mark S ^f   Stüve, Olaf ^g,h   Rieckmann, Peter ⁱ   Montalban, Xavier ^j   Ziemssen, Tjalf ^k   Auberson, Lixin Zhang ^l   Pohlmann, Harald ^l   Mercier, Francois ^l   Dahlke, Frank ^l   Wallström, Erik ^l  

^a MEDICAL UNIVERSITY OF LODZ   (Poland)

^b UNIVERSITY OF BRITISH COLUMBIA   (Canada)

^c HEINRICH HEINE UNIVERSITY   (Germany)

^d TECHNICAL UNIVERSITY OF MUNICH   (Germany)

^e UNIVERSITY HOSPITAL BASEL   (Switzerland)

^f UNIVERSITY OF OTTAWA   (Canada)

^g UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

^h VA North Texas Health Care System   (United States)

ⁱ Sozialstiftung Bamberg Hospital   (Germany)

^j HOSPITAL UNIVERSITARI VALL D HEBRON   (Spain)

^k DRESDEN UNIVERSITY OF TECHNOLOGY   (Germany)

^l NOVARTIS PHARMA AG   (Switzerland)

more..

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO; SIPONIMOD;

ACUTE PYELONEPHRITIS; ARTICLE; BACKACHE; BASAL CELL CARCINOMA; BOLD SIGNAL; BRADYCARDIA; BRONCHITIS; CONTROLLED STUDY; COUGHING; DIZZINESS; DOSE RESPONSE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG FEVER; DRUG SAFETY; DRUG WITHDRAWAL; DYSPNEA; FATIGUE; FEMALE; HEADACHE; HEART INFARCTION; HEART RATE; HUMAN; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MALE; MIGRAINE; MULTICENTER STUDY; MULTIPLE SCLEROSIS; MYOPATHY; NUCLEAR MAGNETIC RESONANCE IMAGING; OPTIC NEURITIS; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PRURITUS; RANDOMIZED CONTROLLED TRIAL; RHINOPHARYNGITIS; SCHIZOPHRENIFORM DISORDER; SECOND DEGREE ATRIOVENTRICULAR BLOCK; SIDE EFFECT; SINUSITIS; SOMNOLENCE; SUICIDE ATTEMPT; UNSPECIFIED SIDE EFFECT; UPPER RESPIRATORY TRACT INFECTION; URINARY TRACT INFECTION; UTERUS MYOMA; VERTIGO; VOMITING;

ADOLESCENT; ADULT; AZETIDINES; BAYES THEOREM; BENZYL COMPOUNDS; BRAIN; COHORT STUDIES; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; FEMALE; HUMANS; MAGNETIC RESONANCE IMAGING; MALE; MIDDLE AGED; MULTIPLE SCLEROSIS, RELAPSING-REMITTING; RECEPTORS, LYSOSPHINGOLIPID; RETROSPECTIVE STUDIES; TIME FACTORS; TREATMENT OUTCOME; YOUNG ADULT;

EID: 84880327078     PISSN: 14744422     EISSN: 14744465     Source Type: Journal    
DOI: 10.1016/S1474-4422(13)70102-9     Document Type: Article

References (12)

1. Brinkmann V Sphingosine 1-phosphate receptors in health and disease: mechanistic insights from gene deletion studies and reverse pharmacology. Pharmacol Ther 2007, 115:84-105.
2. Brinkmann V, Billich A, Baumruker T, et al. Fingolimod (FTY720): discovery and development of an oral drug to treat multiple sclerosis. Nat Rev Drug Discov 2010, 9:883-897.
3. Choi JW, Gardell SE, Herr DR, et al. FTY720 (fingolimod) efficacy in an animal model of multiple sclerosis requires astrocyte sphingosine 1-phosphate receptor 1 (S1P1) modulation. Proc Natl Acad Sci USA 2011, 108:751-756.
4. Soliven B, Miron V, Chun J The neurobiology of sphingosine 1-phosphate signaling and sphingosine 1-phosphate receptor modulators. Neurology 2011, 76:S9-14.
5. Polman CH, Reingold SC, Edan G, et al. Diagnostic criteria for multiple sclerosis: 2005 revisions to the "McDonald Criteria". Ann Neurol 2005, 58:840-846.
6. ICH harmonized tripartite guidelines for good clinical practice (accessed Oct 18, 2010). http://www.ich.org/cache/compo/276-254-1.html.
7. Li DK, Paty DW Magnetic resonance imaging results of the PRISMS trial: a randomized, double-blind, placebo-controlled study of interferon-beta1a in relapsing-remitting multiple sclerosis. Prevention of relapses and disability by interferon-beta1a subcutaneously in multiple sclerosis. Ann Neurol 1999, 46:197-206.
8. Spiegelhalter DJ, Abrams KR, Myles JP Bayesian approaches to clinical trials and health-care evaluation 2003, Wiley, Chichester, UK.
9. Bretz F, Pinheiro JC, Branson M Combining multiple comparisons and modeling techniques in dose-response studies. Biometrics 2005, 61:738-748.
10. Kappos L, Antel J, Comi G, et al. Oral fingolimod (FTY720) for relapsing multiple sclerosis. N Engl J Med 2006, 355:1124-1140.
11. Roesel M, Ruttig A, Schumacher C, Heinz C, Heiligenhaus A Risk factors for the development of macular edema in noninfectious uveitis. Eur J Ophthalmol 2011, 21:625-630.
12. Legangneux E, Gardin A, Johns D Dose titration of BAF312 attenuates the initial heart rate reducing effect in healthy subjects. Br J Clin Pharmacol 2013, 75:831-841.